AAAAAA

   
Results: 1-12 |
Results: 12
Moxifloxacin does increase the corrected QT interval - Reply
Authors: Iannini, PB Tillotson, GS
Citation: Pb. Iannini et Gs. Tillotson, Moxifloxacin does increase the corrected QT interval - Reply, CLIN INF D, 33(8), 2001, pp. 1442-1444
Derriere to the future: Is it time to rethink how we use antimicrobial agents?
Authors: Tillotson, GS
Citation: Gs. Tillotson, Derriere to the future: Is it time to rethink how we use antimicrobial agents?, CLIN INF D, 32(8), 2001, pp. 1189-1190
Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin
Authors: Landen, H Moller, M Tillotson, GS Kubin, R Hoffken, G
Citation: H. Landen et al., Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin, J INT MED R, 29(2), 2001, pp. 51-60
Treatment outcomes in acute exacerbations of chronic bronchitis: Comparison of macrolides and moxifloxacin from the patient perspective
Authors: Lorenz, J Thate-Waschke, IM Mast, O Kubin, R Rychlik, R Pfeil, T Daniel, D Tillotson, GS
Citation: J. Lorenz et al., Treatment outcomes in acute exacerbations of chronic bronchitis: Comparison of macrolides and moxifloxacin from the patient perspective, J INT MED R, 29(2), 2001, pp. 74-86
Hematologic effects of antimicrobials: Focus on the oxazolidinone linezolid
Authors: Kuter, DJ Tillotson, GS
Citation: Dj. Kuter et Gs. Tillotson, Hematologic effects of antimicrobials: Focus on the oxazolidinone linezolid, PHARMACOTHE, 21(8), 2001, pp. 1010-1013
Evaluating the risk of cardiac toxicity
Authors: Iannini, PB Tillotson, GS
Citation: Pb. Iannini et Gs. Tillotson, Evaluating the risk of cardiac toxicity, PHARMACOTHE, 21(3), 2001, pp. 261-262
New milestones achieved in fluoroquinolone safety
Authors: Tillotson, GS Rybak, MJ
Citation: Gs. Tillotson et Mj. Rybak, New milestones achieved in fluoroquinolone safety, PHARMACOTHE, 21(3), 2001, pp. 358-360
Fluoroquinolone pharmacodynamics and efficacy
Authors: Doern, GV Tillotson, GS
Citation: Gv. Doern et Gs. Tillotson, Fluoroquinolone pharmacodynamics and efficacy, CHEST, 120(1), 2001, pp. 319-319
Quinolones and pneumococci
Authors: Tillotson, GS Peterson, LR
Citation: Gs. Tillotson et Lr. Peterson, Quinolones and pneumococci, J ANTIMICRO, 45(5), 2000, pp. 709-710
Implementation and physician behavior change - An industry perspective
Authors: Tillotson, GS
Citation: Gs. Tillotson, Implementation and physician behavior change - An industry perspective, CHEST, 118(2), 2000, pp. 59S-61S
Acute exacerbation of COPD - Factors associated with poor treatment outcome
Authors: Dewan, NA Rafique, S Kanwar, B Satpathy, H Ryschon, K Tillotson, GS Niederman, MS
Citation: Na. Dewan et al., Acute exacerbation of COPD - Factors associated with poor treatment outcome, CHEST, 117(3), 2000, pp. 662-671
Formula to help select rational antimicrobial therapy (FRAT): its application to community- and hospital-acquired urinary tract infections
Authors: Blondeau, JM Tillotson, GS
Citation: Jm. Blondeau et Gs. Tillotson, Formula to help select rational antimicrobial therapy (FRAT): its application to community- and hospital-acquired urinary tract infections, INT J ANT A, 12(2), 1999, pp. 145-150
Risultati: 1-12 |